Patent ID: 11911409
Assignee: STELIC INSTITUTE & CO., INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating a chronic disease of a patient in need thereof, the method comprising: administrating a pharmaceutical composition in combination with a biological preparation that inhibits leukocyte tissue invasion, a biological preparation that inhibits inflammatory cytokines, or a combination thereof, to the patient, wherein the pharmaceutical composition comprises, as an active ingredient: (i) a siRNA that suppresses expression of CHST15 gene comprising a structure formed by hybridizing an RNA comprising the base sequence of SEQ ID NO: 1 with an RNA comprising the base sequence of SEQ ID NO: 2 complementary thereto, (ii) the siRNA of (i) having an overhang from an end thereof, or (iii) a DNA vector expressing the siRNA of (i) or (ii), wherein the biological preparation that inhibits leukocyte tissue invasion comprises at least one member selected from the group consisting of Etrolizumab, Vedolizumab, Natalizumab, PF-00547659 and Vercirnon, and the biological preparation that inhibits inflammatory cytokines comprises at least one member selected from the group consisting of an antibody that inhibits the inflammatory cytokines comprising TNF-a, IL-17, IL-18, IL-23, IL-1p and GM-CSF, an antibody fragment, or a specific binding partner for the inflammatory cytokines which is a single-domain antibody, and wherein the chronic disease is inflammatory bowel disease.